Research programme: tumstatin fusion protein - Ocugen

Drug Profile

Research programme: tumstatin fusion protein - Ocugen

Alternative Names: OCU 200; tumstatin fusion protein - Ocugen

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator University of Colorado at Anschutz Medical Campus
  • Developer Ocugen
  • Class Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 11 Feb 2016 Ocugen receives patent allowance for OCU 200 in USA
  • 05 Jun 2014 Preclinical trials in Wet age-related macular degeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top